These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 34328594)
1. Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson's disease. Yahi N; Di Scala C; Chahinian H; Fantini J Glycoconj J; 2022 Feb; 39(1):1-11. PubMed ID: 34328594 [TBL] [Abstract][Full Text] [Related]
2. AmyP53 Prevents the Formation of Neurotoxic β-Amyloid Oligomers through an Unprecedent Mechanism of Interaction with Gangliosides: Insights for Alzheimer's Disease Therapy. Azzaz F; Chahinian H; Yahi N; Fantini J; Di Scala C Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675271 [TBL] [Abstract][Full Text] [Related]
3. Gene Therapy Strategy for Alzheimer's and Parkinson's Diseases Aimed at Preventing the Formation of Neurotoxic Oligomers in SH-SY5Y Cells. El-Battari A; Rodriguez L; Chahinian H; Delézay O; Fantini J; Yahi N; Di Scala C Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768981 [TBL] [Abstract][Full Text] [Related]
10. The Role of α-Synuclein Oligomers in Parkinson's Disease. Du XY; Xie XX; Liu RT Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33212758 [TBL] [Abstract][Full Text] [Related]
11. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336 [TBL] [Abstract][Full Text] [Related]